Arrowhead's plozasiran cuts acute pancreatitis event rates 78% versus placebo in pooled trials

• Arrowhead Pharmaceuticals presented plozasiran and ARO-DIMER-PA clinical results at the American Heart Association Scientific Sessions 2026.
• Pooled SHASTA-3/4 results showed plozasiran reduced acute pancreatitis rates versus placebo in severe hypertriglyceridemia, particularly among patients with recent pancreatitis.
• The PALISADE extension showed sustained triglyceride reductions through three years in familial chylomicronemia syndrome; findings lacked a concurrent placebo control.
• Early-stage ARO-DIMER-PA results showed simultaneous LDL cholesterol and triglyceride reductions following single doses; reported changes were not placebo-adjusted.
• Injection-site redness was common with ARO-DIMER-PA; no serious adverse events occurred, though longer-term safety and potential cardiovascular benefits require further study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611071615BIZWIRE_USPR_____20261107_BW972891) on November 07, 2026, and is solely responsible for the information contained therein.